SPA Pricing Education, Analytics & Decision Making Tools Webinar Series

Tag: price cap

Novartis price dilemma over $21,000 drug | The Austrailian

Novartis price dilemma over $21,000 drug | The Austrailian

Novartis recently discovered that a drug it sells for a group of very rare diseases could be used to treat a much more common ailment. There is just one problem: its $US16,000-per-dose ($A21,000) price tag. The drug, called ACZ885, is already sold under the brand name Ilaris for certain rare inflammatory disorders affecting a very […]

Drug-Pricing Regulator Wants Medical Devices Added To Price Control List | NDTV Profit

Drug-Pricing Regulator Wants Medical Devices Added To Price Control List | NDTV Profit

India’s drug-pricing regulator has asked the health ministry to add four more medical devices to a list of products eligible for price controls to reduce costs to patients, which if agreed could be another blow to the country’s $5 billion-a-year medical-technology industry. The National Pharmaceutical Pricing Authority (NPPA) had said it did not plan further […]

Company Put Profit Over Patients in Pricing $1,000 Hepatitis Pills: Senate Report | NBC News

Company Put Profit Over Patients in Pricing $1,000 Hepatitis Pills: Senate Report | NBC News

A company that makes two of the priciest drugs on the market was looking to make profits and didn’t care if patients could afford them, a Senate committee said Tuesday. Gilead’s $1,000-a-pill Sovaldi, which can cure hepatitis, has cost the federal government billions and is too expensive for many patients to afford, the Senate Finance […]

Turing announces hospital discount for Daraprim, but no price reduction | The Voice Herald

Turing announces hospital discount for Daraprim, but no price reduction | The Voice Herald

For the past few months, GOOD has followed the story of Martin Shkreli, the former hedge-fund CEO, whose pharmaceutical company bought the rights to Daraprim, a life-saving AIDS drug, and raised its price from $13.50 a pill to an unconscionable $750. Beginning early next year, Turing said it would offer smaller 30-pill bottles for hospitals […]

Turing reneges on drug price cut, rival’s version sells well | Fox News

Turing reneges on drug price cut, rival’s version sells well | Fox News

Turing, with offices in New York and Switzerland, bought U.S. rights to sell Daraprim in August, when it had no competition. Daraprim is one of numerous old drugs with limited competition whose makers have raised prices sharply. A furor over Turing’s staggering price hike erupted, triggering multiple government investigations and pledges from politicians to rein […]

Turing Refuses to Lower List Price of Toxoplasmosis Drug | The New York Times

Turing Refuses to Lower List Price of Toxoplasmosis Drug | The New York Times

Turing Pharmaceuticals, which sparked a fury two months ago by sharply increasing the price of a 62-year-old drug, said on Tuesday that it would not reduce the list price of that drug after all. But it said it would offer discounts of up to 50 percent to hospitals and would take other measures to help […]

The Economics of Drug Pricing | The UCSB Current

The Economics of Drug Pricing | The UCSB Current

“What I have done for many years is go around the world and try to explain why these little pills cost so much,” Comanor said. “That’s what I do.” With his standing in pharmaceutical economics, Comanor has a unique perspective on the recent rash of news and protests about the dramatic rise in some drug […]

Sasol wins polymers pricing case in top court | BDlive

Sasol wins polymers pricing case in top court | BDlive

THE Competition Commission remains concerned about the pricing behaviour of dominant firms in major markets, such as that for polymers, which is why it has so strongly pursued its case against Sasol Chemical Industries (SCI), commission spokesman Itumeleng Lesofe said. He was speaking on Friday after the Constitutional Court dismissed, with costs, the commission’s application […]

Pharma Industry Outlook: Pricing Pressure and M&As in Focus | Zacks.com

Pharma Industry Outlook: Pricing Pressure and M&As in Focus | Zacks.com

The pharma/biotech sector has been in the middle of a controversy, with questions being raised about the high prices of drugs. Democratic presidential frontrunner Hillary Clinton’s “price gouging” tweet triggered a slide in healthcare stocks in September. While there has always been concerns regarding the pricing and affordability of prescription drugs, the issue is back […]

HHS Pharmaceutical Pricing Forum: Lots of Questions, Few Definitive Answers | RAPS

HHS Pharmaceutical Pricing Forum: Lots of Questions, Few Definitive Answers | RAPS

Value The question of drugs’ real-world value cropped up several times at the forum, and this is an issue that seems to be plaguing not only the US (as the New England Journal of Medicine indicated), but other countries as well, particularly with new cancer drugs. Merck Chairman and CEO Ken Frazier noted that one […]